Identification

Name
Losartan
Accession Number
DB00678  (APRD00052)
Type
Small Molecule
Groups
Approved
Description

Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. Losartan and its longer acting metabolite, E-3174, lower blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); they compete with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Losartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of systolic dysfunction, myocardial infarction, coronary artery disease, and heart failure.

Structure
Thumb
Synonyms
  • (2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
  • 2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
  • DuP 89
  • Losartan
External IDs
HGP-1405 / HGP1405 / MK594
Product Ingredients
IngredientUNIICASInChI Key
Losartan Potassium3ST302B24A124750-99-8OXCMYAYHXIHQOA-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act LosartanTablet100 mgOralActavis Pharma Company2012-01-25Not applicableCanada
Act LosartanTablet25 mgOralActavis Pharma Company2012-01-25Not applicableCanada
Act LosartanTablet50 mgOralActavis Pharma Company2012-01-25Not applicableCanada
Ag-losartanTablet100 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-losartanTablet25 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-losartanTablet50 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Auro-losartanTablet25.0 mgOralAuro Pharma Inc2013-03-26Not applicableCanada
Auro-losartanTablet50.0 mgOralAuro Pharma Inc2013-03-26Not applicableCanada
Auro-losartanTablet100.0 mgOralAuro Pharma Inc2013-03-26Not applicableCanada
Bio-losartanTablet50 mgOralBiomed Pharma2016-05-09Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-losartanTablet25 mgOralApotex Corporation2012-04-13Not applicableCanada
Apo-losartanTablet50 mgOralApotex Corporation2012-01-25Not applicableCanada
Apo-losartanTablet100 mgOralApotex Corporation2012-01-25Not applicableCanada
LosartanTablet, film coated50 mg/1OralVirtus Pharmaceuticals2015-07-14Not applicableUs
LosartanTablet, film coated25 mg/1OralMethod Pharmaceuticals2015-07-14Not applicableUs
LosartanTablet, film coated50 mg/1OralA S Medication Solutions2015-07-142017-06-20Us
LosartanTablet, film coated100 mg/1OralVirtus Pharmaceuticals2015-07-14Not applicableUs
LosartanTablet, film coated50 mg/1OralMethod Pharmaceuticals2016-09-20Not applicableUs
LosartanTablet, film coated25 mg/1OralVirtus Pharmaceuticals2015-07-14Not applicableUs
LosartanTablet, film coated100 mg/1OralMethod Pharmaceuticals2016-09-20Not applicableUs
International/Other Brands
Lortaan
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Act Losartan/hctLosartan Potassium (100 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Pharma Company2012-07-03Not applicableCanada
Act Losartan/hctLosartan Potassium (50 mg) + Hydrochlorothiazide (12.5 mg)TabletOralActavis Pharma Company2012-07-03Not applicableCanada
Act Losartan/hctLosartan Potassium (100 mg) + Hydrochlorothiazide (25 mg)TabletOralActavis Pharma Company2012-07-03Not applicableCanada
Apo-losartan/hctzLosartan Potassium (50 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2012-01-25Not applicableCanada
Apo-losartan/hctzLosartan Potassium (100 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2012-01-25Not applicableCanada
Apo-losartan/hctzLosartan Potassium (100 mg) + Hydrochlorothiazide (25 mg)TabletOralApotex Corporation2012-01-25Not applicableCanada
Auro-losartan HctLosartan Potassium (100 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-losartan HctLosartan Potassium (100 mg) + Hydrochlorothiazide (25 mg)TabletOralAuro Pharma Inc2014-04-29Not applicableCanada
Auro-losartan HctLosartan Potassium (50 mg) + Hydrochlorothiazide (12.5 mg)TabletOralAuro Pharma Inc2014-04-29Not applicableCanada
HyzaarLosartan Potassium (50 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralMerck Sharp & Dohme Limited1995-04-28Not applicableUs
Categories
UNII
JMS50MPO89
CAS number
114798-26-4
Weight
Average: 422.911
Monoisotopic: 422.162187095
Chemical Formula
C22H23ClN6O
InChI Key
PSIFNNKUMBGKDQ-UHFFFAOYSA-N
InChI
InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
IUPAC Name
[2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol
SMILES
CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1

Pharmacology

Indication

May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.

Structured Indications
Pharmacodynamics

Losartan is the first of a class of antihypertensive agents called angiotensin II receptor blockers (ARBs). Losartan and its longer acting active metabolite, E-3174, are specific and selective type-1 angiotensin II receptor (AT1) antagonists which block the blood pressure increasing effects angiotensin II via the renin-angiotensin-aldosterone system (RAAS). RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: AT1 and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.

Mechanism of action

Losartan competitively inhibits the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. Losartan is metabolized to its active metabolite, E-3174, which is 10 to 40 times more potent than losartan and acts as a non-competitive AT1 antagonist. Inhibition of angiotensin II binding to AT1 inhibits its AT1-mediated vasoconstrictive and aldosterone-secreting effects and results in decreased vascular resistance and blood pressure. Losartan is 1,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion. Losartan is effective for reducing blood pressure and may be used to treat essential hypertension, left ventricular hypertrophy and diabetic nephropathy.

TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Human
Absorption

Losartan is well absorbed and undergoes substantial first-pass metabolism; the systemic bioavailability of losartan is approximately 33%. Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively. While maximum plasma concentrations of losartan and its active metabolite are approximately equal, the AUC of the metabolite is about 4 times as great as that of losartan. When given with a meal, absorption is slows down and Cmax decreases.

Volume of distribution
  • 34 L [losartan, healthy subjects]
  • 12 L [active metabolite, healthy subjects]
Protein binding

99.7% protein bound, primarily to albumin

Metabolism

Hepatic. Losartan is metabolized to a 5-carboxylic acid derivative (E-3174) via an aldehyde intermediate (E-3179) primarily by cytochrome P450 (CYP) 2C9 and CYP3A4. E-3174 is an active metabolite with 10- to 40-fold higher potency than its parent compound, losartan. Approxiamtely 14% of losartan is converted to E-3174; however, the AUC of E-3174 was found to be 4- to 8-fold higher than losartan and E-3174 is considered the main contributor to the pharmacologic effects of this medication.

Route of elimination

Following oral administration of losartan, 35% of the dose is recovered in the urine and about 60% in the feces. Following an intravenous dose, 45% is recovered in the urine and 50% in the feces.

Half life

The terminal t1/2 of losartan is 2 hours. The active metabolite has a half-life of 6-9 hours.

Clearance
  • Total plasma clearance = 600 mL/min [losartan]
  • Total plasma clearance = 50 mL/min [active metabolite]
  • Renal clearance = 75 mL/min [losartan]
  • Renal clearance = 25 mL/min [active metabolite]
Toxicity

Hypotension and tachycardia; Bradycardia could occur from parasympathetic (vagal) stimulation, LD50= 1000 mg/kg (orally in rat)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Losartan Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Losartan can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe metabolism of Losartan can be decreased when combined with 2-mercaptobenzothiazole.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Losartan.Experimental
AbirateroneThe serum concentration of Losartan can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Losartan is combined with Acebutolol.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Losartan.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Losartan is combined with Acemetacin.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Losartan.Approved
AcetaminophenThe serum concentration of Losartan can be increased when it is combined with Acetaminophen.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Losartan.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Losartan is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Losartan.Approved
AlbendazoleThe serum concentration of Losartan can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclofenacThe risk or severity of adverse effects can be increased when Losartan is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Losartan.Approved
AldosteroneThe serum concentration of Losartan can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Losartan can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Losartan can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Losartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Losartan.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Losartan.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Alminoprofen.Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Losartan.Approved, Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Losartan.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Losartan.Approved, Illicit, Investigational
AlprenololLosartan may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmantadineThe serum concentration of Losartan can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Losartan.Approved, Investigational
AmifostineLosartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Losartan.Approved
Aminohippuric acidThe serum concentration of Losartan can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Losartan.Approved, Withdrawn
AmiodaroneThe metabolism of Losartan can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Losartan.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Losartan.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Losartan.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Losartan.Approved
AmorolfineThe metabolism of Losartan can be decreased when combined with Amorolfine.Approved
Amphotericin BThe metabolism of Losartan can be decreased when combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Losartan can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Losartan can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Losartan is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Losartan is combined with Andrographolide.Investigational
AnidulafunginThe metabolism of Losartan can be decreased when combined with Anidulafungin.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Losartan is combined with Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Losartan.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Losartan.Approved
ApocyninThe risk or severity of adverse effects can be increased when Losartan is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Losartan.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Losartan is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Losartan is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Losartan can be increased when it is combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Losartan.Experimental
ArdeparinArdeparin may increase the hyperkalemic activities of Losartan.Approved, Withdrawn
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Losartan.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Losartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Losartan.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Losartan.Approved, Investigational
ArtemetherThe metabolism of Losartan can be decreased when combined with Artemether.Approved
AstemizoleThe serum concentration of Losartan can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Losartan can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Losartan.Approved
AtomoxetineThe metabolism of Losartan can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Losartan is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Losartan.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Azapropazone.Withdrawn
AzelastineThe serum concentration of Losartan can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Losartan is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Losartan can be increased when it is combined with Azithromycin.Approved
Bafilomycin A1The metabolism of Losartan can be decreased when combined with Bafilomycin A1.Experimental
BalsalazideThe risk or severity of adverse effects can be increased when Losartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Losartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Losartan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Losartan.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Losartan.Approved, Investigational
BemiparinBemiparin may increase the hyperkalemic activities of Losartan.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Losartan is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Losartan is combined with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Losartan.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Losartan.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Losartan is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Benoxaprofen.Withdrawn
BenzocaineThe serum concentration of Losartan can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe metabolism of Losartan can be decreased when combined with Benzoic Acid.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Losartan.Approved
BepridilThe serum concentration of Losartan can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Losartan.Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Losartan.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Losartan.Approved
BethanidineBethanidine may increase the hypotensive activities of Losartan.Approved
BevoniumThe risk or severity of adverse effects can be increased when Losartan is combined with Bevonium.Experimental
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Losartan.Approved, Investigational
BietaserpineBietaserpine may increase the hypotensive activities of Losartan.Experimental
BifonazoleThe metabolism of Losartan can be decreased when combined with Bifonazole.Approved
BimatoprostLosartan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Losartan can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Losartan.Approved
BoceprevirThe metabolism of Losartan can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Losartan can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Losartan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Losartan.Approved
BQ-123Losartan may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe metabolism of Losartan can be decreased when combined with 1,6,7,8,9,11A,12,13,14,14A-DECAHYDRO-1,13-DIHYDROXY-6-METHYL-4H-CYCLOPENT[F]OXACYCLOTRIDECIN-4-ONE.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Losartan.Approved
BretyliumThe risk or severity of adverse effects can be increased when Losartan is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Losartan.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Losartan.Approved, Investigational
BrofaromineBrofaromine may increase the hypotensive activities of Losartan.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Losartan is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Losartan.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Losartan.Approved
BucillamineThe risk or severity of adverse effects can be increased when Losartan is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Losartan is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Losartan is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Losartan is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Losartan.Approved, Investigational
BupranololLosartan may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Losartan can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Losartan.Approved
BuspironeThe serum concentration of Losartan can be increased when it is combined with Buspirone.Approved, Investigational
ButenafineThe metabolism of Losartan can be decreased when combined with Butenafine.Approved
ButoconazoleThe metabolism of Losartan can be decreased when combined with Butoconazole.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Losartan.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Losartan.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Losartan.Approved
CadralazineCadralazine may increase the hypotensive activities of Losartan.Experimental
CafedrineLosartan may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Losartan.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Losartan.Experimental
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Losartan.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Losartan is combined with Candesartan.Approved
CandicidinThe metabolism of Losartan can be decreased when combined with Candicidin.Withdrawn
CandoxatrilThe risk or severity of adverse effects can be increased when Losartan is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Losartan can be decreased when combined with Capecitabine.Approved, Investigational
Capric acidThe metabolism of Losartan can be decreased when combined with Capric acid.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Captopril.Approved
CarbamazepineThe metabolism of Losartan can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Losartan is combined with Carbaspirin calcium.Experimental
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Losartan.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Losartan.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Losartan.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Losartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Losartan.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Losartan.Approved, Investigational
CaspofunginThe metabolism of Losartan can be decreased when combined with Caspofungin.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Losartan is combined with Castanospermine.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Losartan.Approved, Investigational
CeliprololLosartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Losartan can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Losartan.Withdrawn
CertoparinCertoparin may increase the hyperkalemic activities of Losartan.Approved
CeruleninThe metabolism of Losartan can be decreased when combined with Cerulenin.Approved
ChloroquineThe serum concentration of Losartan can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Losartan is combined with Chlorothiazide.Approved, Vet Approved
ChloroxineThe metabolism of Losartan can be decreased when combined with Chloroxine.Approved
ChlorpromazineThe serum concentration of Losartan can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Losartan can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Losartan can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Losartan.Approved
CholecalciferolThe metabolism of Losartan can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Losartan can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Losartan can be decreased when it is combined with Cholic Acid.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Losartan is combined with Choline magnesium trisalicylate.Approved
CicletanineLosartan may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe metabolism of Losartan can be decreased when combined with Ciclopirox.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Losartan.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Losartan.Approved
CimetidineThe serum concentration of Losartan can be decreased when it is combined with Cimetidine.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Losartan.Approved
CiprofloxacinLosartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Losartan.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Losartan.Approved
ClarithromycinThe metabolism of Losartan can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Losartan can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Losartan is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Losartan.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Losartan.Approved, Investigational
ClofazimineThe serum concentration of Losartan can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Losartan.Approved, Investigational
ClomipramineThe serum concentration of Losartan can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Losartan.Approved
ClonixinThe risk or severity of adverse effects can be increased when Losartan is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Losartan.Approved, Nutraceutical
CloranololLosartan may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Losartan can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Losartan.Approved
CobicistatThe metabolism of Losartan can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Losartan.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Losartan.Approved
ColforsinThe serum concentration of Losartan can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Losartan can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Losartan.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Losartan.Approved
CordycepinThe metabolism of Losartan can be decreased when combined with Cordycepin.Investigational
CrisaboroleThe metabolism of Losartan can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Losartan can be decreased when combined with Crizotinib.Approved
CryptenamineLosartan may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Losartan is combined with Curcumin.Investigational
CyclopenthiazideLosartan may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe serum concentration of Losartan can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Losartan can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Losartan.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Losartan is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Losartan.Approved
DabrafenibThe serum concentration of Losartan can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Losartan can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Losartan can be increased when it is combined with Dactinomycin.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Losartan.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Losartan is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Losartan.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Losartan.Approved, Investigational
DarunavirThe metabolism of Losartan can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Losartan.Approved
DasatinibThe serum concentration of Losartan can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Losartan can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Losartan.Approved
DeferasiroxThe serum concentration of Losartan can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Delapril.Experimental
DelavirdineThe metabolism of Losartan can be decreased when combined with Delavirdine.Approved
DeserpidineLosartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Losartan.Approved
DesipramineThe serum concentration of Losartan can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Losartan can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Losartan can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Losartan.Approved, Vet Approved
DextromethorphanThe serum concentration of Losartan can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Losartan.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Losartan.Approved
DichloropheneThe metabolism of Losartan can be decreased when combined with Dichlorophene.Vet Approved
DiclofenacThe serum concentration of Losartan can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Losartan is combined with Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Losartan.Approved
diethylnorspermineLosartan may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Losartan.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Losartan is combined with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Losartan is combined with Diflunisal.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Losartan.Approved
DigoxinThe serum concentration of Losartan can be decreased when it is combined with Digoxin.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Losartan.Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Losartan.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Losartan.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Losartan.Experimental
DihydroergotamineThe metabolism of Losartan can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Losartan.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Losartan.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Losartan is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Losartan.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Losartan is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Losartan.Approved, Investigational
DoconexentThe metabolism of Doconexent can be decreased when combined with Losartan.Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Losartan.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Losartan.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Losartan.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Losartan.Approved
DosulepinThe metabolism of Losartan can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Losartan.Approved
DoxepinThe serum concentration of Losartan can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Losartan.Approved, Investigational
DoxorubicinThe serum concentration of Losartan can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Losartan can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Losartan.Approved, Illicit
DronedaroneThe metabolism of Losartan can be decreased when combined with Dronedarone.Approved
DrospirenoneLosartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Losartan is combined with Droxicam.Approved
DuloxetineLosartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Losartan is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Losartan is combined with E-6201.Investigational
EconazoleThe metabolism of Losartan can be decreased when combined with Econazole.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Losartan.Approved
EfavirenzThe metabolism of Losartan can be decreased when combined with Efavirenz.Approved, Investigational
EfinaconazoleThe metabolism of Losartan can be decreased when combined with Efinaconazole.Approved
EfonidipineLosartan may increase the hypotensive activities of Efonidipine.Approved
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Losartan.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Losartan.Approved, Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Losartan.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Losartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Losartan is combined with Enalaprilat.Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Losartan.Approved
EndralazineEndralazine may increase the hypotensive activities of Losartan.Experimental
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Losartan.Approved
EnzalutamideThe serum concentration of Losartan can be decreased when it is combined with Enzalutamide.Approved
EpanololLosartan may increase the hypotensive activities of Epanolol.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Losartan.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Losartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Losartan.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Losartan.Approved
EprosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Eprosartan.Approved
ErgonovineThe serum concentration of Losartan can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Losartan can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Losartan.Approved, Investigational
ErythromycinThe metabolism of Losartan can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Losartan.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Losartan can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Losartan can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Losartan can be decreased when it is combined with Estrone.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Losartan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Losartan is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Losartan is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Losartan.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Losartan is combined with Etofenamate.Approved
EtoposideThe serum concentration of Losartan can be increased when it is combined with Etoposide.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Losartan.Approved, Investigational
EtravirineThe serum concentration of Losartan can be increased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Losartan is combined with Evening primrose oil.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Losartan.Approved
exisulindThe risk or severity of adverse effects can be increased when Losartan is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Losartan.Approved
FelbinacThe risk or severity of adverse effects can be increased when Losartan is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Losartan is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Losartan is combined with Fenbufen.Approved
FenoldopamLosartan may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Fenoprofen.Approved
FentanylThe serum concentration of Losartan can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Losartan is combined with Fentiazac.Experimental
FenticonazoleThe metabolism of Losartan can be decreased when combined with Fenticonazole.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Feprazone.Experimental
Ferulic acidLosartan may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Losartan.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Losartan.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Losartan.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Losartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Losartan is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Losartan can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Losartan can be decreased when it is combined with Fluconazole.Approved
FlucytosineThe metabolism of Losartan can be decreased when combined with Flucytosine.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Losartan.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Losartan.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Losartan is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Flunoxaprofen.Experimental
FluorouracilThe metabolism of Losartan can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Losartan can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Losartan can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Losartan can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Losartan can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Losartan.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Losartan.Approved
FlutrimazoleThe metabolism of Losartan can be decreased when combined with Flutrimazole.Experimental
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Losartan.Approved
FluvoxamineThe metabolism of Losartan can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Losartan.Approved, Investigational
FosamprenavirThe metabolism of Losartan can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Losartan can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Losartan can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Losartan.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Losartan is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Losartan can be increased when it is combined with Fusidic Acid.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Losartan.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Losartan.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Losartan.Approved
GemfibrozilThe metabolism of Losartan can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Losartan can be increased when it is combined with Genistein.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Losartan.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Losartan.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Losartan.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Losartan.Approved
GlyburideThe serum concentration of Losartan can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Losartan can be increased when it is combined with Glycerin.Approved, Investigational
GlyphosateThe metabolism of Losartan can be decreased when combined with Glyphosate.Experimental
Gramicidin DThe serum concentration of Losartan can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Losartan.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Losartan.Withdrawn
GriseofulvinThe metabolism of Losartan can be decreased when combined with Griseofulvin.Approved, Vet Approved
GuacetisalThe risk or severity of adverse effects can be increased when Losartan is combined with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Losartan.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Losartan.Approved
GuanazodineLosartan may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Losartan.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Losartan is combined with Guanfacine.Approved, Investigational
GuanoclorLosartan may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzLosartan may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanLosartan may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe metabolism of Losartan can be decreased when combined with Hachimycin.Experimental
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Losartan.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Losartan.Approved
HaloproginThe metabolism of Losartan can be decreased when combined with Haloprogin.Approved, Withdrawn
HalothaneThe metabolism of Halothane can be decreased when combined with Losartan.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Losartan.Experimental
HeparinHeparin may increase the hyperkalemic activities of Losartan.Approved, Investigational
HexamethoniumLosartan may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe metabolism of Losartan can be decreased when combined with Hexetidine.Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Losartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Losartan is combined with Higenamine.Investigational
HistamineThe metabolism of Histamine can be decreased when combined with Losartan.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Losartan.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Losartan is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Losartan is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Losartan.Approved, Vet Approved
HydroflumethiazideLosartan may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Losartan.Approved, Illicit
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Losartan.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Losartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Losartan is combined with Icatibant.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Losartan.Approved
IdelalisibThe serum concentration of Losartan can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Losartan.Approved
IloprostIloprost may increase the hypotensive activities of Losartan.Approved, Investigational
ImatinibThe metabolism of Losartan can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Losartan is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Losartan.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Losartan.Approved
IndapamideThe risk or severity of adverse effects can be increased when Losartan is combined with Indapamide.Approved
IndenololLosartan may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Losartan can be decreased when combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Losartan.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Losartan is combined with Indobufen.Investigational
IndomethacinThe serum concentration of Losartan can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Losartan.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Losartan.Approved
IproclozideIproclozide may increase the hypotensive activities of Losartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Losartan.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Losartan is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Losartan.Approved, Investigational
IsavuconazoniumThe metabolism of Losartan can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Losartan.Approved
IsoconazoleThe metabolism of Losartan can be decreased when combined with Isoconazole.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Losartan.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Losartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Losartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Losartan.Approved
ItraconazoleThe metabolism of Losartan can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Losartan can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Losartan.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Losartan.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Losartan is combined with Kebuzone.Experimental
KetamineThe serum concentration of Losartan can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinKetanserin may increase the hypotensive activities of Losartan.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Losartan.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Losartan.Approved
KetoconazoleThe metabolism of Losartan can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Losartan.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Losartan is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Losartan.Approved
LacidipineLosartan may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Losartan.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Losartan.Approved, Investigational
LansoprazoleThe serum concentration of Losartan can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Losartan can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Losartan.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Losartan.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Losartan.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Losartan.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Losartan.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Losartan.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Losartan.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Losartan.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Losartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Losartan.Approved
LevodopaLosartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Losartan.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Losartan.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Losartan.Approved, Investigational
LevothyroxineThe serum concentration of Losartan can be decreased when it is combined with Levothyroxine.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Losartan.Investigational
LidocaineThe serum concentration of Losartan can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Losartan.Approved
LinsidomineLosartan may increase the hypotensive activities of Linsidomine.Experimental
LiothyronineThe serum concentration of Losartan can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Losartan can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Losartan is combined with Lisofylline.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Losartan.Approved
LithiumThe serum concentration of Lithium can be increased when it is combined with Losartan.Approved
LobeglitazoneThe metabolism of Losartan can be decreased when combined with Lobeglitazone.Approved
LofexidineLosartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Losartan can be increased when it is combined with Lomitapide.Approved
LonazolacThe risk or severity of adverse effects can be increased when Losartan is combined with Lonazolac.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Losartan.Approved
LopinavirThe metabolism of Losartan can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Losartan can be increased when it is combined with Loratadine.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Losartan can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Loxoprofen.Approved
LuliconazoleThe serum concentration of Losartan can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Losartan can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Losartan.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Losartan.Illicit, Withdrawn
MacitentanLosartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Losartan is combined with Magnesium salicylate.Approved
ManidipineLosartan may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Losartan is combined with Mannitol.Approved, Investigational
MaprotilineThe serum concentration of Losartan can be increased when it is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Losartan is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Losartan.Withdrawn
MebendazoleThe serum concentration of Losartan can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Losartan.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Losartan.Approved
MefloquineThe serum concentration of Losartan can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Losartan can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Losartan.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Losartan.Approved, Vet Approved
MepartricinThe metabolism of Losartan can be decreased when combined with Mepartricin.Experimental
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Losartan.Investigational, Withdrawn
MeprobamateThe serum concentration of Losartan can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Losartan is combined with Mesalazine.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Losartan.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Losartan is combined with Metamizole.Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Losartan.Experimental
MethadoneThe serum concentration of Losartan can be increased when it is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Losartan is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Losartan.Approved
MethoserpidineLosartan may increase the hypotensive activities of Methoserpidine.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Losartan.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Losartan.Approved, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Losartan.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Losartan is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Losartan.Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Losartan.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Losartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Losartan.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Losartan.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Losartan.Approved
MetipranololThe risk or severity of adverse effects can be increased when Losartan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Losartan.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Losartan.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Losartan.Approved
MetyrosineLosartan may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe metabolism of Losartan can be decreased when combined with Mevastatin.Experimental
MibefradilThe serum concentration of Losartan can be increased when it is combined with Mibefradil.Withdrawn
MicafunginThe metabolism of Losartan can be decreased when combined with Micafungin.Approved, Investigational
MiconazoleThe metabolism of Losartan can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Losartan can be decreased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe metabolism of Losartan can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Losartan can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe metabolism of Losartan can be decreased when combined with Miltefosine.Approved
MinaprineMinaprine may increase the hypotensive activities of Losartan.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Losartan.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Losartan.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Losartan.Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Losartan.Approved
MitomycinThe serum concentration of Losartan can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Losartan can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Losartan can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Losartan is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Losartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Losartan is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Losartan.Approved
MonensinThe metabolism of Losartan can be decreased when combined with Monensin.Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Losartan.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Losartan.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Losartan.Approved
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Losartan.Investigational
MuzolimineLosartan may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Losartan.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Mycophenolic acid.Approved
MyxothiazolThe metabolism of Losartan can be decreased when combined with Myxothiazol.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Losartan.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Losartan is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Losartan is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Losartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Losartan is combined with Nafamostat.Approved, Investigational
NaftifineThe metabolism of Losartan can be decreased when combined with Naftifine.Approved
NaftopidilLosartan may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Losartan.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Losartan.Approved, Vet Approved
NaltrexoneThe serum concentration of Losartan can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Losartan.Approved, Vet Approved
NaringeninThe serum concentration of Losartan can be increased when it is combined with Naringenin.Experimental
NatamycinThe metabolism of Losartan can be decreased when combined with Natamycin.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Losartan.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Losartan is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Losartan can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Losartan can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Losartan can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Losartan is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Losartan is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Losartan can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Losartan can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Losartan.Withdrawn
NicardipineThe metabolism of Losartan can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Losartan.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Losartan.Approved, Vet Approved
NicorandilNicorandil may increase the hypotensive activities of Losartan.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Losartan.Approved
NifedipineThe risk or severity of adverse effects can be increased when Losartan is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Losartan is combined with Niflumic Acid.Approved
NifuratelThe metabolism of Losartan can be decreased when combined with Nifuratel.Experimental
NiguldipineLosartan may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe metabolism of Losartan can be decreased when combined with Nikkomycin Z.Investigational
NilotinibThe metabolism of Losartan can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineLosartan may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Losartan is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Losartan.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Losartan.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Losartan.Approved
NitrazepamThe serum concentration of Losartan can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Losartan can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Losartan.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Losartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Losartan is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Losartan.Approved
NitroxolineThe metabolism of Losartan can be decreased when combined with Nitroxoline.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Losartan.Approved
NorethisteroneThe serum concentration of Losartan can be decreased when it is combined with Norethisterone.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Losartan.Approved
NystatinThe metabolism of Losartan can be decreased when combined with Nystatin.Approved, Vet Approved
ObinutuzumabLosartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Losartan.Withdrawn
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Losartan.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Losartan.Approved, Investigational
OlaparibThe metabolism of Losartan can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Losartan.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Losartan.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Losartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Losartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Losartan is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Losartan.Approved
OmeprazoleThe serum concentration of Losartan can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe metabolism of Losartan can be decreased when combined with Omoconazole.Experimental
OndansetronThe metabolism of Ondansetron can be decreased when combined with Losartan.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Losartan is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Losartan can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Losartan.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Losartan.Approved
OxiconazoleThe metabolism of Losartan can be decreased when combined with Oxiconazole.Approved
OxprenololLosartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Oxyphenbutazone.Withdrawn
P-NitrophenolThe serum concentration of Losartan can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Losartan can be increased when it is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe metabolism of Losartan can be decreased when combined with pafuramidine.Investigational
PalbociclibThe serum concentration of Losartan can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Losartan can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Losartan.Approved, Investigational
PantoprazoleThe serum concentration of Losartan can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Losartan is combined with Papaverine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Losartan.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Losartan.Approved
PargylinePargyline may increase the hypotensive activities of Losartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Losartan.Approved
ParoxetineThe serum concentration of Losartan can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Losartan is combined with Parthenolide.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Losartan.Approved
PenbutololThe risk or severity of adverse effects can be increased when Losartan is combined with Penbutolol.Approved, Investigational
PentamidineThe metabolism of Losartan can be decreased when combined with Pentamidine.Approved
PentobarbitalThe metabolism of Losartan can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumLosartan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Losartan.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Losartan.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Perindopril.Approved
PerospironeThe metabolism of Perospirone can be decreased when combined with Losartan.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Losartan.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Losartan.Withdrawn
PhenelzinePhenelzine may increase the hypotensive activities of Losartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Losartan.Withdrawn
PhenobarbitalThe metabolism of Losartan can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineLosartan may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Losartan.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Losartan.Approved
PhentolamineLosartan may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Losartan.Approved, Vet Approved
PhenytoinThe metabolism of Losartan can be increased when combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Losartan.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Losartan is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Losartan can be increased when it is combined with Pimozide.Approved
PinacidilPinacidil may increase the hypotensive activities of Losartan.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Losartan is combined with Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Losartan.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Losartan.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Losartan is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Losartan.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Losartan.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Pirprofen.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Losartan.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Losartan.Withdrawn
Platelet Activating FactorThe serum concentration of Losartan can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazideLosartan may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Losartan.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Losartan.Approved
PosaconazoleThe metabolism of Losartan can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Losartan.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Pranoprofen.Experimental
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Losartan.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Losartan.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Losartan.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Losartan.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Losartan.Approved, Vet Approved
PrimidoneThe metabolism of Losartan can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Losartan can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Losartan can be decreased when it is combined with Progesterone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Losartan is combined with Proglumetacin.Experimental
ProguanilThe metabolism of Proguanil can be decreased when combined with Losartan.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Losartan.Approved, Vet Approved
PromethazineThe serum concentration of Losartan can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Losartan is combined with Propacetamol.Approved
PropafenoneThe serum concentration of Losartan can be increased when it is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Losartan.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Proquazone.Experimental
ProtriptylineThe serum concentration of Losartan can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Losartan.Approved
PTC299The risk or severity of adverse effects can be increased when Losartan is combined with PTC299.Investigational
PyrimethamineThe metabolism of Losartan can be decreased when combined with Pyrimethamine.Approved, Vet Approved
PyrrolnitrinThe metabolism of Losartan can be decreased when combined with Pyrrolnitrin.Experimental
QuazepamThe metabolism of Quazepam can be decreased when combined with Losartan.Approved, Illicit
QuercetinThe serum concentration of Losartan can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Losartan is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Losartan can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Losartan can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Losartan.Approved
RabeprazoleThe metabolism of Losartan can be decreased when combined with Rabeprazole.Approved, Investigational
RadicicolThe metabolism of Losartan can be decreased when combined with Radicicol.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Losartan is combined with Ramipril.Approved
RanitidineThe serum concentration of Losartan can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Losartan.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Losartan.Approved
ReboxetineThe serum concentration of Losartan can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Losartan can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Losartan.Approved
RemikirenRemikiren may increase the hypotensive activities of Losartan.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Losartan.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Losartan is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Losartan.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Losartan is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Losartan.Approved
RifabutinThe metabolism of Losartan can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Losartan can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Losartan can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Losartan.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Losartan.Investigational
RilpivirineThe serum concentration of Losartan can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Losartan is combined with Riociguat.Approved
RisperidoneLosartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Losartan can be decreased when combined with Ritonavir.Approved, Investigational
RituximabLosartan may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Losartan.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Losartan.Investigational, Withdrawn
RolapitantThe serum concentration of Losartan can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Losartan.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Losartan.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Losartan.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Losartan.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Losartan.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Losartan.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Losartan.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Losartan.Approved
SafrazineSafrazine may increase the hypotensive activities of Losartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Losartan is combined with Salicylamide.Approved
Salicylhydroxamic AcidThe metabolism of Losartan can be decreased when combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe metabolism of Losartan can be decreased when combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Losartan is combined with Salsalate.Approved
SaprisartanLosartan may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Losartan can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Losartan can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Losartan can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Losartan can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Losartan.Approved
SemapimodThe risk or severity of adverse effects can be increased when Losartan is combined with Semapimod.Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Losartan.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Losartan is combined with Serrapeptase.Investigational
SertaconazoleThe metabolism of Losartan can be decreased when combined with Sertaconazole.Approved
SertralineThe serum concentration of Losartan can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Losartan.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Losartan.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Losartan.Approved
SiltuximabThe serum concentration of Losartan can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Losartan can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Losartan can be increased when it is combined with Simvastatin.Approved
SinefunginThe metabolism of Losartan can be decreased when combined with Sinefungin.Experimental
SirolimusThe metabolism of Losartan can be decreased when combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Losartan.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Losartan.Approved
Sodium phosphateLosartan may increase the nephrotoxic activities of Sodium phosphate.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Losartan.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Losartan.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Losartan.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Losartan.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Losartan.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Losartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Losartan.Approved
SRT501The risk or severity of adverse effects can be increased when Losartan is combined with SRT501.Investigational
St. John's WortThe serum concentration of Losartan can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Losartan can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Losartan can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Losartan.Approved
StreptozocinThe serum concentration of Losartan can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Losartan.Approved, Investigational
SulconazoleThe metabolism of Losartan can be decreased when combined with Sulconazole.Approved
SulfadiazineThe metabolism of Losartan can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Losartan.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Losartan.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Losartan is combined with Sulfasalazine.Approved
SulfinpyrazoneThe serum concentration of Losartan can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Losartan can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Losartan is combined with Sulindac.Approved
SumatriptanThe serum concentration of Losartan can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Losartan can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Losartan.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Losartan is combined with Suxibuzone.Experimental
TacrineThe serum concentration of Losartan can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Losartan can be decreased when it is combined with Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Losartan.Approved, Investigational
TalinololLosartan may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe serum concentration of Losartan can be decreased when it is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Losartan.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Losartan.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Losartan is combined with Tarenflurbil.Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Losartan.Experimental
TavaboroleThe metabolism of Losartan can be decreased when combined with Tavaborole.Approved
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Losartan.Approved, Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Losartan.Approved
TelaprevirThe metabolism of Losartan can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Losartan can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Losartan is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Losartan.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Losartan.Approved
TenidapThe risk or severity of adverse effects can be increased when Losartan is combined with Tenidap.Experimental
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Losartan.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Losartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Losartan is combined with Terazosin.Approved
TerbinafineThe metabolism of Losartan can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe metabolism of Losartan can be decreased when combined with Terconazole.Approved
TerfenadineThe serum concentration of Losartan can be increased when it is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Losartan.Experimental
TeriflunomideThe metabolism of Losartan can be decreased when combined with Teriflunomide.Approved
TerlipressinLosartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe serum concentration of Losartan can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Losartan can be increased when it is combined with Testosterone.Approved, Investigational
TetrahydropalmatineLosartan may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
TheodrenalineLosartan may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Losartan.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Losartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Losartan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Losartan.Withdrawn
ThymolThe metabolism of Losartan can be decreased when combined with Thymol.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Tiaprofenic acid.Approved
TiboloneLosartan may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Losartan.Approved
TiclopidineThe metabolism of Losartan can be decreased when combined with Ticlopidine.Approved
TicrynafenLosartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Losartan.Approved
TinoridineThe risk or severity of adverse effects can be increased when Losartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Losartan.Approved
TioconazoleThe metabolism of Losartan can be decreased when combined with Tioconazole.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Losartan.Approved
TocilizumabThe serum concentration of Losartan can be decreased when it is combined with Tocilizumab.Approved
TolazolineLosartan may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Losartan can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Losartan.Approved, Withdrawn
TolciclateThe metabolism of Losartan can be decreased when combined with Tolciclate.Experimental
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Losartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Losartan is combined with Tolmetin.Approved
TolnaftateThe metabolism of Losartan can be decreased when combined with Tolnaftate.Approved, Vet Approved
TolonidineLosartan may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Losartan.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Losartan.Approved, Investigational
TolvaptanTolvaptan may increase the hyperkalemic activities of Losartan.Approved
TopiroxostatThe metabolism of Losartan can be decreased when combined with Topiroxostat.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Losartan.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Losartan.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Losartan.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Losartan.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Losartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Losartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Losartan.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Losartan.Approved
TravoprostTravoprost may increase the hypotensive activities of Losartan.Approved
TrazodoneThe serum concentration of Losartan can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Losartan.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Losartan.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Losartan.Approved
TribenosideThe risk or severity of adverse effects can be increased when Losartan is combined with Tribenoside.Experimental
TrichlormethiazideLosartan may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Losartan can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Losartan can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Losartan.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Losartan.Approved
TrimethaphanTrimethaphan may increase the hypotensive activities of Losartan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Losartan.Approved, Vet Approved
TrimetrexateThe metabolism of Losartan can be decreased when combined with Trimetrexate.Approved, Investigational
TrimipramineThe serum concentration of Losartan can be increased when it is combined with Trimipramine.Approved
TriptolideThe risk or severity of adverse effects can be increased when Losartan is combined with Triptolide.Investigational
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Losartan.Withdrawn
TroleandomycinThe serum concentration of Losartan can be increased when it is combined with Troleandomycin.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Losartan.Experimental
UdenafilUdenafil may increase the antihypertensive activities of Losartan.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Losartan.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Losartan.Approved
UnoprostoneLosartan may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Losartan.Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Losartan.Investigational, Withdrawn
Valproic AcidThe metabolism of Losartan can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Losartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Losartan.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Losartan.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Losartan.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Losartan.Approved
VenlafaxineThe metabolism of Losartan can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Losartan.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Losartan.Investigational
VinblastineThe serum concentration of Losartan can be decreased when it is combined with Vinblastine.Approved
VincamineLosartan may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Losartan.Approved, Investigational
VincristineThe serum concentration of Losartan can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Losartan can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineLosartan may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Losartan.Approved
VoriconazoleThe metabolism of Losartan can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Losartan.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Losartan.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Losartan.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
XipamideLosartan may increase the hypotensive activities of Xipamide.Experimental
XylometazolineLosartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Losartan.Approved, Vet Approved
ZafirlukastThe metabolism of Losartan can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Losartan.Approved
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Losartan.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Losartan.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Losartan can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Losartan can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Zofenopril.Experimental
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Losartan.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Losartan is combined with Zomepirac.Withdrawn
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Losartan.Approved
Food Interactions
  • Take without regard to meals. Take at same time each day. Food delays absorption, but does not affect the extent of absorption.

References

Synthesis Reference

Gordon C. Campbell, Jr., Anil M. Dwivedi, Dorothy A. Levorse, James A. McCauley, Krishnaswamy S. Raghavan, "Polymorphs of losartan and the process for the preparation of form II of losartan." U.S. Patent US5608075, issued May, 1994.

US5608075
General References
  1. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003. [PubMed:11937178]
  2. Guo ZX, Qiu MC: [Losartan downregulates the expression of transforming growth factor beta type I and type II receptors in kidney of diabetic rat]. Zhonghua Nei Ke Za Zhi. 2003 Jun;42(6):403-8. [PubMed:12895325]
  3. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC: Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 7;312(5770):117-21. [PubMed:16601194]
  4. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066]
  5. Stanfield, Cindy L.;Germann, William J. (2009). Principles of Human Physiology (3rd ed.). Benjamin-Cummings Publishing Company. [ISBN:978-0321556660]
  6. Bader, M. (2004). Renin-angiotensin-aldosterone system. In Encyclopedic reference of molecular pharmacology (pp. 810-814). Berlin: Springer. [ISBN:9783540298328]
External Links
Human Metabolome Database
HMDB14816
KEGG Drug
D08146
KEGG Compound
C07072
PubChem Compound
3961
PubChem Substance
46506538
ChemSpider
3824
BindingDB
82258
ChEBI
6541
ChEMBL
CHEMBL191
Therapeutic Targets Database
DAP000523
PharmGKB
PA450268
IUPHAR
590
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Losartan
ATC Codes
C09DA01 — Losartan and diureticsC09DB06 — Losartan and amlodipineC09CA01 — Losartan
AHFS Codes
  • 24:32.08 — Angiotensin Ii Receptor Antagonists
FDA label
Download (212 KB)
MSDS
Download (19 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic SciencePeripheral Arterial Disease (PAD)1
0CompletedDiagnosticPostural Tachycardia Syndrome1
0CompletedTreatmentDiabetic Nephropathies1
0CompletedTreatmentSickle Cell Disorders1
0Not Yet RecruitingTreatmentBlood Pressures / Hypertensive1
1CompletedNot AvailableHealthy Volunteers11
1CompletedNot AvailableKidney Diseases1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHypertension(HTN)1
1CompletedBasic ScienceHypertensive / Multiple System Atrophy (MSA) / Progressive autonomic failure1
1CompletedDiagnosticCytochrome / Pharmacokinetics1
1CompletedDiagnosticHypertensive1
1CompletedHealth Services ResearchHealthy Volunteers2
1CompletedTreatmentCardiovascular Disease (CVD)1
1CompletedTreatmentFasting1
1CompletedTreatmentHyperlipidemias / Hypertensive1
1CompletedTreatmentHypertensive4
1Unknown StatusTreatmentHealthy Volunteers1
1, 2CompletedTreatmentAging1
1, 2RecruitingTreatmentChildren / Pulmonary vein stenosis1
1, 2RecruitingTreatmentDisseminated Sclerosis1
1, 2RecruitingTreatmentHamstring Injury1
1, 2TerminatedTreatmentAlbinism, Oculocutaneous / Hermansky-Pudlak Syndrome (HPS) / Metabolic Diseases / Platelet Storage Pool Deficiency / Pulmonary Fibrosis1
2Active Not RecruitingTreatmentConnective Tissue Disorders / Oesophagitis, Eosinophilic1
2CompletedNot AvailableDiabetes, Diabetes Mellitus Type 11
2CompletedPreventionSarcopenia1
2CompletedTreatmentChronic Kidney Disease (CKD) / Hyperkalemia / Hypertensive1
2CompletedTreatmentDiabetic Macular Edema (DME)1
2CompletedTreatmentGlomerulosclerosis, Focal Segmental1
2CompletedTreatmentHypertensive1
2CompletedTreatmentHypertensive / Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour)1
2CompletedTreatmentHypertrophic Cardiomyopathy2
2CompletedTreatmentMarfan Syndrome1
2CompletedTreatmentNAFLD1
2CompletedTreatmentRenal Dysfunction / Sickle Cell Disorders1
2CompletedTreatmentTransplant, Kidney1
2Not Yet RecruitingTreatmentCystic Fibrosis (CF)1
2RecruitingPreventionHyperlipidemias / Hypertensive1
2RecruitingPreventionInflammatory Reaction1
2RecruitingPreventionStress Disorders, Post-Traumatic1
2RecruitingTreatmentHeart Defects,Congenital / Tetralogy Of Fallot / Ventricular Dysfunction, Right1
2RecruitingTreatmentHigh Blood Pressure / Hypertensive1
2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2RecruitingTreatmentHypertensive1
2RecruitingTreatmentHypertensive / Kidney Diseases / Proteinuria / Sickle Cell Disorders1
2RecruitingTreatmentMalignant Neoplasm of Pancreas1
2RecruitingTreatmentOesophagitis, Eosinophilic1
2TerminatedTreatmentHypertensive1
2TerminatedTreatmentHypertensive / Unspecified Adult Solid Tumor, Protocol Specific1
2TerminatedTreatmentPre-Diabetic / Pre-Hypertension1
2Unknown StatusPreventionMarfan Syndrome1
2Unknown StatusTreatmentHypertension,Essential1
2Unknown StatusTreatmentNonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis1
2, 3CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF) / Pulmonary Fibrosis1
2, 3RecruitingPreventionCognitively Normal Older Adults / Family History of Alzheimer's Disease / Hypertensive / Subjective Cognitive Decline1
2, 3TerminatedTreatmentDiabetic Nephropathies1
2, 3WithdrawnTreatmentHypertensive1
3Active Not RecruitingTreatmentNewly-diagnosed Glioblastoma1
3CompletedPreventionLung Cancers / Nonvalvular Atrial Fibrillation1
3CompletedTreatmentArterial Hypertension1
3CompletedTreatmentBMI >27 kg/m2 / Hypertensive / Left Ventricular Hypertrophy1
3CompletedTreatmentCardiovascular Disease (CVD) / Hypertensive1
3CompletedTreatmentDiabetic Nephropathies1
3CompletedTreatmentDiabetic Nephropathies / Proteinuria / Renal Diseases / Type 2 Diabetes Mellitus1
3CompletedTreatmentHeart Failure, Unspecified1
3CompletedTreatmentHyperlipidemias / Hypertension,Essential1
3CompletedTreatmentHypertension,Essential2
3CompletedTreatmentHypertension,Essential / Impaired Renal Function1
3CompletedTreatmentHypertension; Hypertrophy, Left Ventricular1
3CompletedTreatmentHypertensive16
3CompletedTreatmentHypertensive / Metabolic Disorders1
3CompletedTreatmentMarfan Syndrome2
3CompletedTreatmentNonalcoholic Steatohepatitis1
3CompletedTreatmentProteinuria1
3CompletedTreatmentPulmonary Hypertension (PH)1
3Not Yet RecruitingTreatmentCerebral Small Vessels Disease1
3Not Yet RecruitingTreatmentHypertensive1
3RecruitingTreatmentChronic Kidney Disease (CKD)1
3RecruitingTreatmentHypertensive1
3RecruitingTreatmentIgA Glomerulonephritis1
3RecruitingTreatmentMarfan Syndrome1
3TerminatedTreatmentHypertensive1
3TerminatedTreatmentKidney Diseases / Renal Dysfunction / Type 2 Diabetes Mellitus1
3TerminatedTreatmentMarfan Syndrome1
3Unknown StatusPreventionMarfan Syndrome1
3Unknown StatusTreatmentDiabetes Mellitus (DM) / Hypertension,Essential1
3Unknown StatusTreatmentMarfan Syndrome1
3Unknown StatusTreatmentProteinuria1
3Unknown StatusTreatmentSevere Sepsis1
3WithdrawnPreventionHyperoxaluria1
3WithdrawnTreatmentEssential Arterial Hypertension2
4Active Not RecruitingTreatmentHypertensive1
4CompletedNot AvailableBMI >30 kg/m2 / Hyperglycemias / Hypertensive1
4CompletedBasic ScienceRejection, Transplant1
4CompletedDiagnosticHyperaldosteronism1
4CompletedPreventionDiabetic Nephropathies1
4CompletedPreventionKidney Diseases / Proteinuria1
4CompletedPreventionRenal Stones1
4CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Fibrosis, Liver1
4CompletedTreatmentCongestive Heart Failure (CHF) / Low Cardiac Output1
4CompletedTreatmentDiabetes Mellitus (DM) / Hypertensive1
4CompletedTreatmentDiabetic Nephropathies / Hypertensive1
4CompletedTreatmentHeart Failure, Unspecified1
4CompletedTreatmentHigh Blood Pressure / Hypertension,Essential1
4CompletedTreatmentHypertensive8
4CompletedTreatmentHypertensive / Impaired Glucose Tolerance (IGT)1
4CompletedTreatmentHypertensive / Insulin Resistance / Metabolic Syndromes1
4CompletedTreatmentHypertensive / Left Ventricle Hypertrophy1
4CompletedTreatmentHypertensive / Metabolic Syndromes1
4CompletedTreatmentHypertensive / Pharmacogenetics1
4CompletedTreatmentHypertensive / Sleep Apnea Syndrome1
4CompletedTreatmentHypertensive / Strokes1
4CompletedTreatmentInfection, Human Immunodeficiency Virus I1
4CompletedTreatmentKidney Diseases1
4CompletedTreatmentLiver Transplant Recipients1
4CompletedTreatmentMacroalbuminuric Diabetic Nephropathy1
4CompletedTreatmentStage 2 Systolic Hypertension1
4CompletedTreatmentStroke, Ischemic1
4Not Yet RecruitingTreatmentCrohn's Disease (CD) / Ulcerative Colitis (UC)1
4RecruitingPreventionBlood Pressures / Hypertensive / Strokes1
4RecruitingTreatmentBipolar Disorder (BD) / Cardiovascular Disease (CVD) / Major Depressive Disorder (MDD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Serious Mental Illness1
4RecruitingTreatmentEmphysema1
4RecruitingTreatmentGlomerulonephritis / Proteinuria1
4RecruitingTreatmentIgA Nephropathy1
4SuspendedTreatmentEnd Stage Renal Disease (ESRD) / Hypertensive / Proteinuria1
4TerminatedPreventionAtherosclerosis / Carotid Artery Stenosis / Strokes1
4TerminatedPreventionDiabetes Mellitus (DM) / Hypertensive1
4Unknown StatusPreventionAlcoholic Liver Cirrhosis / Ascites1
4Unknown StatusTreatmentBlood Pressures1
4Unknown StatusTreatmentChronic Bronchitis / Chronic Obstructive Pulmonary Disease (COPD) / Emphysema / Smoking1
4Unknown StatusTreatmentHypertension, Resistant to Conventional Therapy / Hypertension,Essential1
4Unknown StatusTreatmentHypertension,Essential1
4Unknown StatusTreatmentHypertensive3
4WithdrawnTreatmentHeart Failure, Unspecified1
Not AvailableActive Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
Not AvailableCompletedNot AvailableAging / Hypertensive1
Not AvailableCompletedNot AvailableHealthy Normotensive Participants1
Not AvailableCompletedNot AvailableHypertensive2
Not AvailableCompletedNot AvailableHypertrophic Cardiomyopathy / Left Ventricular Hypertrophy / Myocardial Ischemia1
Not AvailableCompletedBasic ScienceInsulin Resistance / Type 2 Diabetes Mellitus1
Not AvailableCompletedBasic ScienceMemory, Long-Term / Memory, Short-Term1
Not AvailableCompletedDiagnosticHypertensive1
Not AvailableCompletedPreventionLeft Ventricular Hypertrophy / Renal Failure1
Not AvailableCompletedTreatmentAlbuminuria1
Not AvailableCompletedTreatmentAngiotensin II Type 1 Receptor Blockers / Diabetic Nephropathies / Glucose Metabolism / Obese / Type 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Impaired Glucose Tolerance (IGT) / Insulin Resistance / Pre-Diabetic1
Not AvailableCompletedTreatmentDiabetic Nephropathies1
Not AvailableCompletedTreatmentDiabetic Nephropathies / Proteinuria1
Not AvailableCompletedTreatmentDiabetic Nephropathies / Type 2 Diabetes Mellitus2
Not AvailableCompletedTreatmentDuchenne's Muscular Dystrophy (DMD) / Prophylaxis of cardiomyopathy1
Not AvailableCompletedTreatmentHigh Blood Pressure1
Not AvailableCompletedTreatmentHypertensive5
Not AvailableCompletedTreatmentMicroalbuminuria1
Not AvailableCompletedTreatmentPrecancerous Conditions1
Not AvailableNot Yet RecruitingPreventionAging / Hypertensive / Sedentary Lifestyle1
Not AvailableRecruitingBasic ScienceChronic Bronchitis / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableRecruitingTreatmentIgA Nephropathy1
Not AvailableRecruitingTreatmentPosttraumatic Stress Disorders1
Not AvailableTerminatedScreeningCytochrome P450 Phenotype and Genotype Metrics1
Not AvailableTerminatedTreatmentACE Inhibitor / Angiotensin II Type 1 Receptor Blockers / Dose-Response Relationship, Drug / Progression, Disease / Proteinuria / Renal Insufficiency,Chronic1
Not AvailableTerminatedTreatmentRenal Insufficiency,Chronic1
Not AvailableUnknown StatusNot AvailableAtherosclerosis / Diabetes Mellitus (DM)1
Not AvailableUnknown StatusNot AvailableHypertensive2
Not AvailableUnknown StatusTreatmentAngiotensin II Type 1 Receptor Blockers / Angiotensin-Converting Enzyme Inhibitors / Chronic Kidney Insufficiency / Proteinuria1
Not AvailableUnknown StatusTreatmentBicuspid Aortic Valve (BAV) / Thoracic Aortic Aneurysm (TAA)1
Not AvailableUnknown StatusTreatmentChronic Renal Diseases1
Not AvailableUnknown StatusTreatmentIgA Glomerulonephritis1
Not AvailableUnknown StatusTreatmentNonvalvular Atrial Fibrillation1
Not AvailableWithdrawnSupportive CareDyspnea / Lung Cancers / Pulmonary Complications / Radiation Fibrosis1

Pharmacoeconomics

Manufacturers
  • Merck research laboratories div merck co inc
  • Teva pharmaceuticals usa inc
  • Merck & Co., Inc.
Packagers
Dosage forms
FormRouteStrength
TabletOral100.0 mg
TabletOral25.0 mg
TabletOral50.0 mg
TabletOral100 mg
TabletOral25 mg
TabletOral25 mg/1
TabletOral50 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coatedOral
TabletOral100 mg/1
TabletOral50 mg/1
TabletOral
Prices
Unit descriptionCostUnit
Losartan Potassium 90 50 mg tablet Bottle211.78USD bottle
Losartan Potassium-HCTZ 30 50-12.5 mg tablet Bottle78.05USD bottle
Hyzaar 100-25 mg tablet3.91USD tablet
Hyzaar 100-12.5 mg tablet3.87USD tablet
Hyzaar 100-12.5 tablet3.61USD tablet
Hyzaar 100-25 tablet3.61USD tablet
Losartan Potassium-HCTZ 100-12.5 mg tablet3.54USD tablet
Losartan Potassium-HCTZ 100-25 mg tablet3.54USD tablet
Cozaar 100 mg tablet3.41USD tablet
Losartan potassium 100 mg tablet3.14USD tablet
Hyzaar 50-12.5 mg tablet2.97USD tablet
Hyzaar 50-12.5 tablet2.65USD tablet
Cozaar 50 mg tablet2.5USD tablet
Losartan potassium 50 mg tablet2.26USD tablet
Cozaar 25 mg tablet1.92USD tablet
Losartan potassium 25 mg tablet1.72USD tablet
Cozaar 100 mg Tablet1.31USD tablet
Cozaar 25 mg Tablet1.31USD tablet
Cozaar 50 mg Tablet1.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5210079No1993-11-112010-11-11Us
US5608075No1992-03-042009-03-04Us
CA2085584No2003-02-112011-06-07Canada
CA1334092No1995-01-242012-01-24Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)184 °CPhysProp
water solubility0.82 mg/LNot Available
logP6.1Not Available
pKa5.5MERCK INDEX (1996); approx.
Predicted Properties
PropertyValueSource
Water Solubility0.0047 mg/mLALOGPS
logP4.5ALOGPS
logP5.08ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)7.4ChemAxon
pKa (Strongest Basic)4.12ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.51 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity131.85 m3·mol-1ChemAxon
Polarizability44.86 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier-0.7812
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.6993
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IIInhibitor0.5309
Renal organic cation transporterNon-inhibitor0.5689
CYP450 2C9 substrateNon-substrate0.6839
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.6226
CYP450 1A2 substrateInhibitor0.5514
CYP450 2C9 inhibitorNon-inhibitor0.5423
CYP450 2D6 inhibitorNon-inhibitor0.8102
CYP450 2C19 inhibitorInhibitor0.6288
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7049
Ames testNon AMES toxic0.5382
CarcinogenicityNon-carcinogens0.6595
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6055 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5781
hERG inhibition (predictor II)Inhibitor0.8084
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0000900000-657db16bb4bfe9184114
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-056r-0900000000-43bb8508cd1dbc71bcee
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-55368087829d113fdb7b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-af470646c547613f82a0
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-746dcf7a43a3f8839c1d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-0bee80f7ccbc4b68eee0
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-d845ae166a10faff242a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-2900000000-d39a309c02e1aaa956b0
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-7900000000-d27d10ab008deb157e7a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00fr-0900700000-fef78a7f52d4aa515bb4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00fr-0900600000-c62f0db44e17f79e0c70
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0034900000-22ba49ec64d374c8965e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0191000000-8ff1b5a21f6ef4a462cd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0590000000-9841ff7f881c3e9c11b9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a59-0960000000-a24e287a018dae01dd0d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a5c-0930000000-ff3e675bd445225bf04e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0pxu-0920000000-9adf4aef59fc1545fea6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0v00-1900000000-3591888cf5831cbe3d11
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0wmi-2900000000-ab9304c8cebc201d0178
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0j70-5900000000-efa87b7770206ac0ff3e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0491300000-f4b08850a154cfc2117c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0591300000-32a922edf20b3eb76950

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Phenyltetrazoles and derivatives / 1,2,4,5-tetrasubstituted imidazoles / N-substituted imidazoles / Aryl chlorides / Heteroaromatic compounds / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organochlorides
show 2 more
Substituents
Biphenyl / Phenyltetrazole / 1,2,4,5-tetrasubstituted imidazole / Aryl chloride / Aryl halide / N-substituted imidazole / Azole / Heteroaromatic compound / Imidazole / Tetrazole
show 14 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
imidazoles, biphenylyltetrazole (CHEBI:6541)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Sardo MA, Castaldo M, Cinquegrani M, Bonaiuto M, Fontana L, Campo S, Campo GM, Altavilla D, Saitta A: Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients. Angiology. 2004 Mar-Apr;55(2):195-203. [PubMed:15026875]
  3. Dickstein K, Timmermans P, Segal R: Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure. Expert Opin Investig Drugs. 1998 Nov;7(11):1897-914. [PubMed:15991937]
  4. Anand-Srivastava MB, Palaparti A: Angiotensin-II-induced enhanced expression of Gi proteins is attenuated by losartan in A10 vascular smooth muscle cells: role of AT1 receptors. Can J Physiol Pharmacol. 2003 Feb;81(2):150-8. [PubMed:12710529]
  5. Rocha I, Bras-Rosario L, Amparo-Barros M, Silva-Carvalho L: Angiotensin AT1 receptor antagonist losartan and the defence reaction in the anaesthetised rat. Effect on the carotid chemoreflex. Exp Physiol. 2003 May;88(3):309-14. [PubMed:12719755]
  6. Guan J, Cheng DY, Chen XJ, Zhang Y, Wang H, Su QL: [The effects of losartan on pulmonary arterial collagen and AT1 in chronic hypoxic rats]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004 Nov;35(6):774-7. [PubMed:15573751]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Song JC, White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000 Feb;20(2):130-9. [PubMed:10678291]
  2. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F, Eliasson E, Dahl ML: Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther. 2002 Jan;71(1):89-98. [PubMed:11823761]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Song JC, White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000 Feb;20(2):130-9. [PubMed:10678291]
  2. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein kinase c binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A10
Uniprot ID
Q9HAW8
Uniprot Name
UDP-glucuronosyltransferase 1-10
Molecular Weight
59809.075 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. The major substrates of this isozyme are eugenol > 4-methylumbe...
Gene Name
UGT2B17
Uniprot ID
O75795
Uniprot Name
UDP-glucuronosyltransferase 2B17
Molecular Weight
61094.915 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100]
  2. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. [PubMed:8621716]
  3. Soldner A, Benet LZ, Mutschler E, Christians U: Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar;129(6):1235-43. [PubMed:10725273]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Urate transmembrane transporter activity
Specific Function
Required for efficient urate re-absorption in the kidney. Regulates blood urate levels. Mediates saturable urate uptake by facilitating the exchange of urate against organic anions.
Gene Name
SLC22A12
Uniprot ID
Q96S37
Uniprot Name
Solute carrier family 22 member 12
Molecular Weight
59629.57 Da
References
  1. Lipkowitz MS: Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012 Apr;14(2):179-88. doi: 10.1007/s11926-012-0240-z. [PubMed:22359229]
  2. Burnier M, Roch-Ramel F, Brunner HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996 Jun;49(6):1787-90. [PubMed:8743498]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sugar:proton symporter activity
Specific Function
Transport urate and fructose. May have a role in the urate reabsorption by proximal tubules. Also transports glucose at low rate.
Gene Name
SLC2A9
Uniprot ID
Q9NRM0
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 9
Molecular Weight
58701.205 Da
References
  1. Lipkowitz MS: Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012 Apr;14(2):179-88. doi: 10.1007/s11926-012-0240-z. [PubMed:22359229]
  2. Burnier M, Roch-Ramel F, Brunner HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996 Jun;49(6):1787-90. [PubMed:8743498]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13